Clinical Trials Using pan-RAF Kinase Inhibitor TAK-580
Clinical trials are research studies that involve people. The clinical trials on this list are studying pan-RAF Kinase Inhibitor TAK-580. All trials on the list are supported by NCI.
NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.
TAK-580 in Treating Patients with Recurrent Low-Grade Gliomas or Other RAS / RAF / MEK / ERK Pathway Activated Tumors
This phase I trial studies the best dose of pan-RAF kinase inhibitor TAK-580 (TAK-580) and to see how well it works in patients with low-grade gliomas or other RAS / RAF / MEK / ERK pathway activated tumors that have come back. TAK-580 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Location: 13 locations
A Study to Evaluate DAY101 in Pediatric and Young Adult Patients With Relapsed or Progressive Low-Grade Glioma
FIREFLY-1 is a Phase 2, multi center, open-label study to evaluate the safety and efficacy of oral pan-RAF inhibitor DAY101 in pediatric, adolescent, and young adult patients with recurrent or progressive low-grade glioma harboring a known BRAF alteration.
Location: 3 locations